Eidos Therapeutics, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced operating income was USD 6.251 million compared to operating loss of USD 10.988 million a year ago. Net income was USD 6.931 million compared to net loss of USD 10.614 million a year ago. Basic earnings per share was USD 0.19 compared to basic loss per share of USD 0.3 a year ago. Diluted earnings per share was USD 0.18 compared to diluted loss per share of USD 0.3 a year ago. For the nine months, operating loss was USD 21.127 million compared to USD 27.074 million a year ago. Net loss was USD 18.855 million compared to USD 30.871 million a year ago. Basic loss per share was USD 0.52 compared to USD 1.83 a year ago.